3-Nitro-naphthalimide and nitrogen mustard conjugate NNM-25 induces hepatocellular carcinoma apoptosis via PARP-1/p53 pathway

Apoptosis

Volumn 17, Issue 7, 2012, Pages 725-734

  Xie, Song Qiang ^a   Zhang, Ya Hong ^a   Li, Qian ^a   Xu, Feng Hua ^a   Miao, Jiu Wang ^a   Zhao, Jin ^a   Wang, Chao Jie ^a  

^a HENAN UNIVERSITY   (China)

Author keywords

Alkylating agent; Apoptosis; Hepatocellular carcinoma; Naphthalimide; PARP 1

Indexed keywords

3 NITRONAPHTHALIMIDE; ANTINEOPLASTIC AGENT; CASPASE 8; CASPASE 9; CHLORMETHINE DERIVATIVE; CYTOCHROME C; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NNM 25; PROTEIN BAD; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; DRUG SCREENING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; RNA INTERFERENCE; TUMOR CELL DESTRUCTION; UPREGULATION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DNA, NEOPLASM; FLUORESCENCE; HUMANS; INTERCALATING AGENTS; LIVER NEOPLASMS; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; NAPHTHALIMIDES; NEOPLASM PROTEINS; NITROGEN MUSTARD COMPOUNDS; POLY(ADP-RIBOSE) POLYMERASES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84862822433     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-012-0712-7     Document Type: Article

References (23)

1. Alves RC, Alves D, Guz B, Matos C, Viana M, Harriz M (2011) Advanced hepatocellular carcinoma. Review of targeted molecular drugs. Ann Hepatol 10:21-27
2. Duffy A, Greten T (2010) Developing better treatments in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 4:551-560
3. Ingrassia L, Lefranc F, Kiss R, Mijatovic T (2010) Naphthalimides and azonafides as promising anti-cancer agents. Curr Med Chem 16:1192-1213
4. Tian ZY, Xie SQ, Du YW, Ma YF, Zhao J, Gao WY, Wang CJ (2009) Synthesis, cytotoxicity and apoptosis of naphthalimide polyamine conjugates as antitumor agents. Eur J Med Chem 44:393-399
5. Tian ZY, Xie SQ, Mei ZH, Zhao J, Gao WY, Wang CJ (2010) Conjugation of substituted naphthalimides to polyamines as cytotoxic agents targeting the Akt/mTOR signal pathway. Org Biomol Chem 7:4651-4660
6. Pain A, Samanta S, Dutta S, Saxena AK, Shanmugavel M, Kampasi H, Quazi GN, Sanyal U (2003) Synthesis and evaluation of substituted naphthalimide nitrogen mustards as rationally designed anticancer compounds. Acta Pol Pharm 60:285-291 (Pubitemid 37279470)
7. Horton JK, Stefanick DF, Zeng JY, Carrozza MJ, Wilson SH (2011) Requirement for NBS1 in the S phase checkpoint response to DNA methylation combined with PARP inhibitory. DNA Repair 10:225-234
8. Powell C, Mikropoulos C, Kaye SB, Nutting CM, Bhide SA, Newbold K (2010) Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers. Cancer Treat Rev 36:566-575
9. Rodon J, Iniesta MD, Papadopoulos K (2009) Development of PARP inhibitors in oncology. Expert Opin Investig Drugs 18:31-43
10. Heacock ML, Stefanick DF, Horton JK, Wilson SH (2010) Alkylation DNA damage in combination with PARP inhibitory results in formation of S-phase-dependent double-strand breaks. DNA Repair 9:929-936
11. Wang S, Jia L, Zhou H, Shi W, Zhang J (2009) Knockdown of caveolin-1 by siRNA inhibits the transformation of mouse hepatoma H22 cells in vitro and in vivo. Oligonucleotides 19:81-88
12. Kuang DM, Peng C, Zhao Q, Wu Y, Chen MS, Zheng L (2010) Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology 51:154-164
13. Xie SQ, Li Q, Zhang YH, Wang JH, Mei ZH, Zhao J, Wang CJ (2011) NPC-16, a novel naphthalimide-polyamine conjugate, induced apoptosis and autophagy in human hepatoma HepG2 cells and Bel-7402 cells. Apoptosis 16:27-34
14. Alano CC, Kauppinen TM, Valls AV, Swanson RA (2006) Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci USA 103:9685-9690 (Pubitemid 43955885)
15. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O, Gusterson B, Bell AK, Heath V, Tavassoli M, Farrell PJ, Smith P, Lu X, Crook T (2003) p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3:387-402 (Pubitemid 38340307)
16. Van Quaquebeke E, Mahieu T, Dumont P, Dewelle J, Ribaucour F, Simon G, Sauvage S, Gaussin JF, Tuti J, El Yazidi M, Van Vynckt F, Mijatovic T, Lefranc F, Darro F, Kiss R (2007) 2,2,2-Trichloro-N-({2-[2-(dimethylamino)ethyl]-1,3- dioxo-2,3-dihydro-1H-benzo [de]isoquinolin-5-yl}carbamoyl)acetamide (UNBS3157), a novel non-hematotoxic naphthalimide derivative with potent antitumor activity. J Med Chem 50:4122-4134 (Pubitemid 47301744)
17. Pain A, Samanta S, Dutta S, Saxena AK, Shanmugavel M, Kampasi H (2003) Evaluation of naphthalmustine, a nitrogen mustard derivative of naphthalimide as a rationally-designed anticancer agent. J Exp Clin Cancer Res 22:411-418 (Pubitemid 37205398)
18. Sandhu SK, Yap TA, de Bono JS (2010) Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur J Cancer 46:9-20
19. Löser DA, Shibata A, Shibata AK, Woodbine LJ, Jeggo PA (2010) Chalmers, sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Mol Cancer Ther 9:1775-1787
20. Huang SH, Xiong M, Chen XP, Xiao ZY, Zhao YF, Huang ZY (2008) PJ34, an inhibitor of PARP-1, suppresses cell growth and enhances the suppressive effects of cisplatin in liver cancer cells. Oncol Rep 20:567-572
21. Fiorillo C, Ponziani V, Giannini L, Cecchi C, Celli A, Nassi N, Lanzilao L, Caporale R, Nassi P (2006) Protective effects of the PARP-1 inhibitor PJ34 in hypoxic-reoxygenated cardiomyoblasts. Cell Mol Life Sci 63:3061-3071 (Pubitemid 46072308)
22. Pu T, Zhang XP, Liu F, Wang W (2010) Coordination of the nuclear and cytoplasmic activities of p53 in response to DNA damage. Biophys J 99:1696-1705
23. Smith ML, Kumar MA (2010) The "two faces" of tumor suppressor p53-revisited. Mol Cell Pharmacol 2:117-119